Although no direct comparisons are available, ponatinib appears to provide the highest probability of achieving ≤1% BCR::ABL1IS and higher rates of OS compared with second-generation TKIs in the third-line treatment setting of patients with CP-CML with and without the T315I mutation [21, 24–27]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.